Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2745517rdf:typepubmed:Citationlld:pubmed
pubmed-article:2745517lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:2745517lifeskim:mentionsumls-concept:C2349001lld:lifeskim
pubmed-article:2745517lifeskim:mentionsumls-concept:C0681850lld:lifeskim
pubmed-article:2745517lifeskim:mentionsumls-concept:C1706203lld:lifeskim
pubmed-article:2745517lifeskim:mentionsumls-concept:C2697811lld:lifeskim
pubmed-article:2745517lifeskim:mentionsumls-concept:C0007202lld:lifeskim
pubmed-article:2745517lifeskim:mentionsumls-concept:C0152021lld:lifeskim
pubmed-article:2745517lifeskim:mentionsumls-concept:C0019134lld:lifeskim
pubmed-article:2745517lifeskim:mentionsumls-concept:C0332580lld:lifeskim
pubmed-article:2745517lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:2745517lifeskim:mentionsumls-concept:C1550501lld:lifeskim
pubmed-article:2745517pubmed:issue3lld:pubmed
pubmed-article:2745517pubmed:dateCreated1989-8-17lld:pubmed
pubmed-article:2745517pubmed:abstractTextFour groups of patients were studied. Group I: Congenital cyanotic heart disease (CCHD), consisting of 24 subjects aged 5 to 28 (1.4); 18 males and 4 females. Group II: Acyanotic congenital heart disease (ACHD), consisting of 34 patients aged 5 to 42 (20.1); 17 males and 17 females. Group III: Rheumatic heart disease (RHD), consisting of 30 patients aged 11-54 (42.4); 9 males and 21 females. Group IV: Atherosclerotic heart disease (AHD), consisting of 35 patients aged 36 to 65 (49.2); 33 males and 2 females. The haematocrit value (Hct) was the highest in the CCHD group. Total amount of heparin (mg/kg) used during cardiopulmonary bypass was 5.4 in CCHD, 4.66 in ACHD, 4.8 in RHD and 4.6 in AHD group. Mean protamine values was 4.02; 4; 4.03; and 4 respectively. Although the difference of Hct value was statistically different between CCHD and RHD group (p less than 0.001), heparin need was not (p less than 0.1). One-way analysis of variance (F test) showed no difference for heparin need between the four groups (F3.119 = 0.64). Prothrombin time (PT) and activated partial thromboplastin time (aPTT) showed a positive correlation (r = 0.36 and r = 0.25) with heparin need in CCHD group but no correlation was found in RHD group.lld:pubmed
pubmed-article:2745517pubmed:languageenglld:pubmed
pubmed-article:2745517pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2745517pubmed:citationSubsetIMlld:pubmed
pubmed-article:2745517pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2745517pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2745517pubmed:statusMEDLINElld:pubmed
pubmed-article:2745517pubmed:issn0021-9509lld:pubmed
pubmed-article:2745517pubmed:authorpubmed-author:GöbEElld:pubmed
pubmed-article:2745517pubmed:authorpubmed-author:BayazitKKlld:pubmed
pubmed-article:2745517pubmed:authorpubmed-author:TasdemirOOlld:pubmed
pubmed-article:2745517pubmed:authorpubmed-author:ZorlutunaYYlld:pubmed
pubmed-article:2745517pubmed:authorpubmed-author:YakutCClld:pubmed
pubmed-article:2745517pubmed:authorpubmed-author:BabacanM KMKlld:pubmed
pubmed-article:2745517pubmed:authorpubmed-author:KaragözHHlld:pubmed
pubmed-article:2745517pubmed:issnTypePrintlld:pubmed
pubmed-article:2745517pubmed:volume30lld:pubmed
pubmed-article:2745517pubmed:ownerNLMlld:pubmed
pubmed-article:2745517pubmed:authorsCompleteYlld:pubmed
pubmed-article:2745517pubmed:pagination348-50lld:pubmed
pubmed-article:2745517pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:2745517pubmed:meshHeadingpubmed-meshheading:2745517-...lld:pubmed
pubmed-article:2745517pubmed:meshHeadingpubmed-meshheading:2745517-...lld:pubmed
pubmed-article:2745517pubmed:meshHeadingpubmed-meshheading:2745517-...lld:pubmed
pubmed-article:2745517pubmed:meshHeadingpubmed-meshheading:2745517-...lld:pubmed
pubmed-article:2745517pubmed:meshHeadingpubmed-meshheading:2745517-...lld:pubmed
pubmed-article:2745517pubmed:meshHeadingpubmed-meshheading:2745517-...lld:pubmed
pubmed-article:2745517pubmed:meshHeadingpubmed-meshheading:2745517-...lld:pubmed
pubmed-article:2745517pubmed:meshHeadingpubmed-meshheading:2745517-...lld:pubmed
pubmed-article:2745517pubmed:meshHeadingpubmed-meshheading:2745517-...lld:pubmed
pubmed-article:2745517pubmed:meshHeadingpubmed-meshheading:2745517-...lld:pubmed
pubmed-article:2745517pubmed:meshHeadingpubmed-meshheading:2745517-...lld:pubmed
pubmed-article:2745517pubmed:meshHeadingpubmed-meshheading:2745517-...lld:pubmed
pubmed-article:2745517pubmed:meshHeadingpubmed-meshheading:2745517-...lld:pubmed
pubmed-article:2745517pubmed:meshHeadingpubmed-meshheading:2745517-...lld:pubmed
pubmed-article:2745517pubmed:meshHeadingpubmed-meshheading:2745517-...lld:pubmed
pubmed-article:2745517pubmed:articleTitleHeparin need of the patients with cyanotic congenital heart disease during cardiopulmonary bypass. Comparison of cyanotic, acyanotic, rheumatic and atherosclerotic subjects.lld:pubmed
pubmed-article:2745517pubmed:affiliationTürkiye Yüksek Ihtisas Hospital, Ankara, Turkey.lld:pubmed
pubmed-article:2745517pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2745517pubmed:publicationTypeComparative Studylld:pubmed